lucky calico legit or not

lucky calico legit or not An online debate over foreign workers in tech shows tensions in Trump’s political coalition

Advisors Asset Management Inc. lifted its stake in BridgeBio Pharma, Inc. ( NASDAQ:BBIO – Free Report ) by 56.1% during the third quarter, HoldingsChannel reports. The institutional investor owned 4,576 shares of the company’s stock after acquiring an additional 1,645 shares during the period. Advisors Asset Management Inc.’s holdings in BridgeBio Pharma were worth $117,000 as of its most recent SEC filing. Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD grew its holdings in shares of BridgeBio Pharma by 22.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 803,956 shares of the company’s stock worth $24,859,000 after purchasing an additional 145,594 shares during the last quarter. First Turn Management LLC acquired a new stake in shares of BridgeBio Pharma in the 3rd quarter valued at about $10,178,000. Jennison Associates LLC acquired a new stake in shares of BridgeBio Pharma in the 3rd quarter valued at about $767,000. Comerica Bank grew its stake in BridgeBio Pharma by 3,013.5% during the 1st quarter. Comerica Bank now owns 38,514 shares of the company’s stock worth $1,191,000 after buying an additional 37,277 shares during the last quarter. Finally, Frazier Life Sciences Management L.P. increased its position in BridgeBio Pharma by 6.4% during the second quarter. Frazier Life Sciences Management L.P. now owns 3,632,604 shares of the company’s stock worth $92,014,000 after buying an additional 217,000 shares during the period. 99.85% of the stock is currently owned by institutional investors and hedge funds. BridgeBio Pharma Trading Down 1.5 % Shares of BBIO stock opened at $27.09 on Friday. The stock has a 50 day simple moving average of $25.02 and a 200-day simple moving average of $26.21. The company has a market cap of $5.12 billion, a price-to-earnings ratio of -11.24 and a beta of 1.09. BridgeBio Pharma, Inc. has a 12-month low of $21.62 and a 12-month high of $44.32. Wall Street Analysts Forecast Growth Check Out Our Latest Analysis on BBIO Insider Buying and Selling In other BridgeBio Pharma news, CEO Neil Kumar sold 27,389 shares of the company’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $22.41, for a total transaction of $613,787.49. Following the transaction, the chief executive officer now directly owns 4,897,443 shares in the company, valued at approximately $109,751,697.63. This represents a 0.56 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link . Also, major shareholder Genetic Disorder L.P. Kkr sold 5,800,000 shares of BridgeBio Pharma stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $25.75, for a total transaction of $149,350,000.00. Following the sale, the insider now owns 25,260,971 shares of the company’s stock, valued at approximately $650,470,003.25. The trade was a 18.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here . Insiders have sold 5,831,545 shares of company stock valued at $150,056,923 over the last quarter. Company insiders own 24.66% of the company’s stock. BridgeBio Pharma Profile ( Free Report ) BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. See Also Want to see what other hedge funds are holding BBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BridgeBio Pharma, Inc. ( NASDAQ:BBIO – Free Report ). Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter .ROSEN, LEADING INVESTOR COUNSEL, Encourages Five9, Inc. Investors to Secure Counsel Before ...

Dogecoin is a joke − so what’s behind its rally?The story so far: In light of the legal immunity afforded to U.S. Presidents for official acts, Department of Justice (DOJ) Special Counsel Jack Smith recently moved to drop the charges against President-elect Donald Trump for attempting to overturn the results of the 2020 election, specifically the criminal charges for encouraging a violent mob to attack the U.S. Capitol on January 6, 2021. Mr. Smith’s request was granted by the District Judge hearing the case. What about the other cases? The DOJ has also filed motions to drop all federal charges against Mr. Trump that relate to the latter’s “mishandling” of classified documents. Two state-level cases against him are also in legal limbo: the election interference case in Georgia has been paused pending a decision by an appeals court; in the business fraud case in New York involving charges against Mr. Trump for paying off an adult film star for her silence over an alleged affair, his conviction has been indefinitely delayed. Scot-free: On a major legal reprieve for Donald Trump While the dropping of these charges marks the official end of Democrats’ hopes to hold Mr. Trump liable for several alleged crimes, it remains to be seen as to whether the 45th President will use this clean slate as a springboard to a bipartisan approach to policymaking, or whether it will merely strengthen his hand towards a second inning of the brand of divisive politics that has polarised the electorate of the country in recent years. What are the specific charges against Mr. Trump that have been dropped? Firstly, regarding the classified documents case, Mr. Trump was first indicted in June 2023 on 37 felony counts “related to mishandling classified documents that he took from the White House to his Florida home.” These charges included wilful retention of national defence information, conspiracy to obstruct justice and making false statements. While a Florida judge had earlier dismissed the case and Mr. Smith’s office had sought an appeal, those charges are all being dropped now. In August 2023, Mr. Trump was additionally indicted on four felony charges relating to his attempts to reverse the 2020 election results. These charges included conspiracy to defraud the U.S., conspiracy to obstruct an official proceeding (a reference to the process of certification of the election results by Congress), obstruction of and attempt to obstruct an official proceeding and conspiracy against rights. What view has the U.S. Supreme Court taken on the subject? The Supreme Court in July 2024 handed down its first ruling on the subject of presidential immunity when it determined, by an expected 6-3 majority, that former Presidents enjoyed broad immunity from prosecution. At the time, Chief Justice John Roberts wrote for the majority opinion of the court, “Under our constitutional structure of separated powers, the nature of presidential power entitles a former president to absolute immunity from criminal prosecution for actions within his conclusive and preclusive constitutional authority... And he is entitled to at least presumptive immunity from prosecution for all his official acts. There is no immunity for unofficial acts.” The three liberal dissenting judges criticised the ruling as undermining the “core democratic principle that no person is above the law,” with Justice Sonia Sotomayor writing that “in every use of official power, the President is now a king above the law” and that the protection afforded to Presidents by the court was “just as bad as it sounds, and it is baseless.” Is Mr. Trump absolved of guilt? Not necessarily. In her latest ruling on the cases, District Judge Tanya Chutkan said that she was dismissing the election interference charges against Mr. Trump “without prejudice,” suggesting that the door to prosecuting Mr. Trump in the future has been left open, specifically after Mr. Trump demits office after his second term, and loses his legal immunity shield. Hinting at the DOJ’s view on the matter, Mr. Smith noted that the charges had been dropped because the DOJ “forbids the federal indictment and subsequent criminal prosecution of a sitting President,” while adding the decision to not proceed with the indictments and trials was “not based on the merits or strength of the case against the defendant.” Then there are the political views of liberals and progressives, possibly including a majority of the more than 74 million Americans who voted for Mr. Trump’s rival, incumbent Vice- President and Democrat candidate Kamala Harris, in the November 5 presidential election. While voter views on Mr. Trump may vary widely in general, polling as recently as six months ago found that nearly three in five Americans (59%) agreed that Mr. Trump was guilty of the 34 felony counts on which he was convicted in the New York case, compared to just 32% who believed he was innocent. Another poll around the same time found that a whopping 50% of respondents thought that Mr. Trump’s guilty verdict on all 34 counts in his hush money trial was correct. Similarly, a poll in April this year found that 53% of respondents believed that Mr. Trump committed “serious federal crimes.” Yet the fact that a poll in May 2024 suggested that 67% of voters — including 74% of independents — said that a conviction would make no difference for how they voted in the election offers a deeper insight into the political preferences of voters. Published - December 01, 2024 04:00 am IST Copy link Email Facebook Twitter Telegram LinkedIn WhatsApp Reddit Presidential felony: On the Trump verdict Trump 2.0 | Portentions of a second innings ​Scot-free: On a major legal reprieve for Donald Trump Watch: What led to the rise of Trump? Donald Trump becomes first former U.S. President convicted of felony crimes USA / crime / criminal / The Hindu Explains

Sandstone steps added to Wodi Wodi walking track, but it's still a challengeAlexander Materne, the suspect, reportedly left a 14-year-old girl in this tent in the woods after driving her from Tennessee to Louisiana to have sexual relations with her (Tangipahoa Parish Sheriffs Office) A Louisiana man is facing multiple charges after reportedly driving to Tennessee to pick up a 14-year-old girl, then abandoning her in the woods with only a tent, food and water. A 14-year-old girl reported missing in Tennessee was found safe in Louisiana, where a man she met online left her in the woods after having sexual relations with her. According to the St. Charles Parish Sheriff’s Office , the suspect, 28-year-old Alexander Materne, met the teen girl on a gaming platform online and arranged to drive from Louisiana to Tennessee to pick her up. On Dec. 23, he drove the girl to his home in St. Rose, Louisiana, and had sexual relations with her. When she disclosed her age to him, he reportedly bought the girl a tent, food and water and dropped her off in a secluded wooded area in Tangipahoa Parish, about 42 miles from his house. RELATED: Suspect in custody after allegedly kidnapping child he met on social media, police say From there, Materne reportedly left and went to celebrate Christmas with his family in Jennings, Louisiana, about 160 miles from his home in St. Rose. The teen girl’s parents were able to track Materne to Jennings and get deputies to his family’s house to question him, authorities said. He later took detectives to the girl’s tent in the woods. She’d been there for about two days. The girl was taken to a hospital for a check-up and later reunited with her family. Materne faces numerous charges, including aggravated kidnapping of a child and felony counts of human trafficking and carnal knowledge. "You can’t make this stuff up. It’s a Christmas miracle that she was found safe. This thing could’ve ended badly," Tangipahoa Parish Sheriff Gerald Sticker said. This report includes information from the St. Charles Parish Sheriff's Office and the Associated Press, and photos from the Tangipahoa Parish Sheriff's Office.